ClinicalTrials.gg
Active, not recruitingNCT05439824Updated May 24, 2023

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

A Phase 2 interventional study of SYS6006 20 μg and SYS6006 30 μg in SARS-CoV-2 Infection, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-24.

Sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 472 studies in COVID-19 with a site in China — 53 open to participants now, 75 under way, 8 of them phase 3. COVID-19 · China.

Enrollment
93rd of 330
450 · median 200
Started
2022
with 123 others
Phase 2
48 of 472
4 open now
Primary completion
2023-01
later than 8 of 74 live
Registered
269th of 472
by date

Among the 472 studies in COVID-19 with a site in China, this one is the 93rd largest by enrollment of the 330 interventional ones that give a count, is one of 124 that started in 2022, is one of 48 in phase 2, reaches primary completion later than 8 of the 74 other live ones, and was the 269th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

53 of the 472 studies in COVID-19 with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 472 studies in COVID-19 with a site in China, or all of them as a file.
02

Study summary

This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006)in healthy participants aged 18 or more.

03

Conditions studied

  • SARS-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age at the time of the first dose of vaccine: 18 and above;
  2. Axillary body temperature is less than 37.3 degree centigrade on the day of enrollment;
  3. Based on the medical history, physical examination and laboratory examination results, the investigator clinically determined the qualified person.
  4. Has independent judgment, and participate voluntarily and sign an form.

Exclusion criteria

Exclusion Criteria:

  • Those who meet any of the following criteria must be excluded from this study:

    1. Has a history of SARS or SARS-CoV-2 infection, or close contact with SARS-CoV-2 infected person( nucleic acid test positive), or living abroad within 30 days before screening;
    2. Positive for SARS-CoV-2 antibody test;
    3. History of allergy to paracetamol or vaccination (such as acute allergic reaction, urticaria, dyspnea, angioedema, or abdominal pain);
    4. Has a history of vaccination with SARS-CoV-2 vaccine, or vaccination with other inactivated or recombinant vaccine within 7 days or received within 14 days before the first dose;
    5. Has a medical or family history of epilepsy or convulsion, neurological disorders, mental disorders, etc.;
    6. Is for intramuscular injection, such as diagnosed thrombocytopenia, any coagulation disorder or receiving anticoagulant treatment, etc.;
    7. Has known or suspected serious disorders judged by the Investigator, including but not limited to respiratory disorders (pulmonary failure, etc.), liver and kidney disorders, cardiovascular disorders (cardiac failure, severe hypertension, etc.), malignant tumors, infections or allergic skin disorders, infection, or in the acute infection or chronic disease activity period (within 3 days before vaccination);
    8. Has chronic diseases (such as Down syndrome, sickle cell anemia, neurological disorders and Guillain-Barre syndrome, excluding chronic diseases such as controlled stable diabetes mellitus/hypertension/hyperlipidemia) that are not suitable for this study at the discretion of the Investigator;
    9. Has known immunological impairment or immunodeficiency diagnosed by hospital before enrollment, or functional asplenia or splenectomy caused by any condition;
    10. For women of : positive pregnancy test before the enrollment, being in pregnant, breastfeeding, or have a pregnancy plan within 1 year; men: whose spouses is of childbearing potential and has a pregnancy plan within 1 year;
    11. Is participating or plan to participate in other clinical studies during the study;
    12. Has received immune enhancement or therapy within 3 months (continuous oral or instillation for more than 14 days); or received treatment with whole blood, plasma and immunoglobulin within 1 month;
    13. Is unlikely to adhere to the study procedures or keep appointments at the discretion of the investigators;or has other conditions that are not suitable for participating in this clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
450 participants (actual)

Study arms

  • Experimental
    20 μg dose of SYS6006 (Aged 18~59 years or 60 years or more)

    20μg dose of SYS6006 vaccine IM, on day 0 and day 21.

    Biological: SYS6006 20 μg

  • Experimental
    30 μg dose of SYS6006 (Aged 18~59 years or 60 years or more)

    30 μg dose of SYS6006 vaccine IM, on day 0 and day 21.

    Biological: SYS6006 30 μg

  • Placebo comparator
    Placebo(Aged 18~59 years or 60 years or more)

    placebo IM, on day 0 and day 21 .

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Geometric mean titer (GMT), geometric mean increase (GMI) and seroconversion rate (SCR) of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibody

    Time frame: 14 days after the second dose

  2. Adverse events (AEs), including solicited AEs and unsolicited AEs

    Time frame: From the first dose through 30 days following the second dose

  3. AEs associated with the study intervention

    Time frame: From the first dose through 30 days following the second dose

Secondary outcomes

  1. Serious adverse events (SAEs)

    Time frame: from the first dose through 12 months after the second dose.

  2. Adverse events of special interest (AESIs)

    Time frame: rom the first dose through 12 months after the second dose.

  3. Laboratory test related adverse events

    Time frame: 4 days following each dose.

  4. Geometric Mean Titer(GMT), Geometric Mean Fold Increase (GMI) and Seroconversion Rate (SCR) of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibody

    Time frame: from the first dose through 21 days

  5. GMT, GMI and SCR of serum anti-SARS-CoV-2 neutralizing antibody and IgG antibody

    Time frame: 30, 90, 180 and 360 days after the second dose.

07

Study locations

2 sites
  • Hebei Provincial Center For Disease Control and Prevention
    Shijia Zhuang, Hebei 050024, China
  • Sir Run Run Hosipital Nanjing Medical University
    Nanjing, Jiangsu, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jan 2023, 6 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 6 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jun 30, 2022
StartActual
Jun 28, 2022
Primary completionActual
Jan 12, 2023
CompletionEst.
Jun 28, 2023
Last update
May 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05439824
Responsible party
Sponsor
First posted
Jun 30, 2022
Start date
Jun 28, 2022
Primary completion
Jan 12, 2023
Completion
Jun 28, 2023 (estimated)
Last update
May 24, 2023

Study contacts

Yuliang Zhao
principal investigator · Center For Disease Control and Prevention, Hebei Province
Jingxin Li
principal investigator · Jiangsu Provincial Center for Disease Control and Prevention
Xiang Lu
principal investigator · Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYS6006 COVID-19 vaccine

Start the discussion